Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

Next Previous
Trial Profile

A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Acronyms LANTERN
  • Sponsors Ipsen

Most Recent Events

  • 27 Feb 2017 Status changed from active, no longer recruiting to completed.
  • 30 Jun 2016 Planned End Date changed from 1 Apr 2017 to 1 Jan 2017.
  • 30 Jun 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top